To mitigate this risk, a team led by Jeffrey S. Miller developed a construct named NKG2C–KE, an NKG2C/IL-15/CD33-targeted cytotoxic engager designed to direct NKG2C+ cells toward CD33+ cells, specifically targeting acute myeloid leukemia (AML) cells. The gene discussed is CD33; the disease is acute myeloid leukemia.